Organon is lined up to copy 1 of the blockbuster drugs on this tracker, which earned $3.6B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Organon's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Perjeta Poherdy |
Roche | Biosimilar | 2026 | FDA-approved Nov 2025; not yet launched | ≈$3.6B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not Organon's share of it.